Do prophylactic antilymphocyte globulins (ALG and OKT3) improve renal transplant survival in recipient and donor high-risk groups?
Cecka
J M
JM
Department of Surgery, University of California, Los Angeles 90024.
Gjertson
D
D
Terasaki
P I
PI
D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D002102:Cadaver; D005500:Follow-Up Studies; D006085:Graft Survival / Q000276:immunology*; D006801:Humans; D016030:Kidney Transplantation / Q000276:immunology*; D016853:Muromonab-CD3 / Q000627:therapeutic use*; D012042:Registries; D012189:Retrospective Studies; D012307:Risk Factors; D013997:Time Factors
D000961:Antilymphocyte Serum; D016853:Muromonab-CD3